<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626704</url>
  </required_header>
  <id_info>
    <org_study_id>20060324</org_study_id>
    <nct_id>NCT00626704</nct_id>
  </id_info>
  <brief_title>Phase 1b/2 Study of AMG 655 With Doxorubicin for the First-Line Treatment of Unresectable Soft Tissue Sarcoma</brief_title>
  <official_title>A Phase 1b/2 Study of AMG 655 in Combination With Doxorubicin for the First-Line Treatment of Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1/2, multicenter, randomized, double-blind, placebo-controlled trial is designed
      to evaluate the efficacy and safety of AMG 655 when combined with doxorubicin compared with
      doxorubicin alone in subjects with previously untreated, locally advanced or metastatic,
      unresectable soft tissue sarcoma.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival</measure>
    <time_frame>Length of Study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate, time to response, duration of response, clinical benefit rate, overall survival, incidence of adverse events and clinical laboratory abnormalities, and incidence of anti-AMG 655 antibody formation.</measure>
    <time_frame>Length of Study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">134</enrollment>
  <condition>Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma</condition>
  <condition>Sarcoma</condition>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AMG 655 + Doxorubicin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Doxorubicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 655</intervention_name>
    <description>AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Conatumumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive dummy AMG 655 (to maintain blind)</description>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed soft tissue sarcoma

          -  Locally advanced, recurrent, or metastatic, unresectable disease

          -  Measurable disease according to modified RECIST

          -  ECOG performance status of 0 or 1

          -  Men or women at least 18 years of age

          -  Adequate hematological, renal, hepatic, and coagulation function

        Exclusion Criteria:

          -  Prior treatment with anthracyclines

          -  Uncontrolled cardiovascular disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 14, 2008</study_first_submitted>
  <study_first_submitted_qc>February 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <disposition_first_submitted>March 24, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>March 24, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 14, 2015</disposition_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Soft Tissue Sarcoma</keyword>
  <keyword>Locally Advanced or Metastatic, Unresectable Soft Tissue Sarcoma</keyword>
  <keyword>AMG 655</keyword>
  <keyword>STS</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Death receptor</keyword>
  <keyword>TRAIL receptor</keyword>
  <keyword>Apoptosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

